2004 Drug Development Pharmaceutical Companies 
European Pharmaceutical Review
JULY 7, 2022
Dr Eric Hughes joins Teva with experience in all phases of drug development at global pharmaceutical companies, most recently Boston-based Vertex Pharmaceuticals, which he joined last year. Prior to that, he was Head of the Immunology, Hepatology & Dermatology Global Development Unit at Novartis.
European Pharmaceutical Review
JULY 4, 2024
4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 13 Currently, over 350 herbal remedies have been granted a THR licence.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
FEBRUARY 21, 2023
This year, Novartis has secured the top position with a market cap of $207.65B, followed by Bayer and Lantheus Medical Imaging PharmaShots has compiled a list of the Top 20 Radiopharma Companies developing products as a treatment option, ranked based on their market cap.
Pharmaceutical Technology
APRIL 12, 2023
This is to ensure patient safety, as outlined in The Medicines for Human Use (Clinical Trials) Regulations 2004. These include guidelines on good primate housing systems, minimising non-human primate use in drug development, and generating evidence in areas to refine non-human primate vaccine studies.
PharmaShots
FEBRUARY 20, 2023
After the outbreak of any epidemic or pandemic, all the responsibilities come on the shoulders of pharmaceutical companies. With unprecedented diseases lurking on the corner, pharmaceutical companies, are now obligated to widen their conventional horizons and look for substitute practices in their drug development strategies.
Expert insights. Personalized for you.
98 
Let's personalize your content